A resin composite composition, its preparation method and application
By preparing dextromethorphan and quinidine into resin complexes, and using ion exchange resins to form dextromethorphan resin complexes and quinidine resin complexes, the medication problem for patients with dysphagia is solved, achieving good taste masking and dissolution effects, and is suitable for the preparation of oral formulations that are easy to swallow.
Patent Information
- Application Number
- CN202210522856.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-05-14
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-05-14
AI Technical Summary
Existing dextromethorphanidine compositions are insufficient to meet the medication needs of patients with dysphagia, and existing taste masking agents often hinder the dissolution of the active ingredient, making it difficult to achieve both taste masking and dissolution effects simultaneously.
Dextromethorphan and quinidine are made into resin complexes and then combined with ion exchange resins such as IRP88, IRP70, IRP64, IRP69 or T-114 to form dextromethorphan resin complexes and quinidine resin complexes. By adjusting the amount and concentration of resins added, good taste masking effect and dissolution requirements can be achieved.
It can be used to prepare oral formulations such as granules, orally disintegrating tablets or solutions that are easy to swallow, improve the patient's medication experience, and maintain a similar dissolution effect as the original product. The process is simple and low-cost, and suitable for industrial production.
Smart Images

Figure 327557DEST_PATH_IMAGE002 
Figure 543458DEST_PATH_IMAGE006 
Figure 564875DEST_PATH_IMAGE001
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical preparations, and more specifically to a composition comprising a dextromethorphan resin complex and a quinidine resin complex, a method for preparing the composition, and its application. Background Technology
[0002] Dextromethorphan hydrobromide and quinidine sulfate (brand name: Nuedexta) is a combination drug developed by Avanir Pharmaceuticals Inc. for the treatment of pseudobulbar affective disorder (PBA), and it was first approved by the FDA in October 2010. This drug is the first and only approved treatment for PBA, also known as affective incontinence, which is primarily secondary to neurological diseases such as Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and stroke, and is characterized by sudden, involuntary crying or laughing.
[0003] Dextromethorphan and quinidine have an unpleasant taste, being both bitter and numbing, and are currently available in capsule form. Patients with neurological disorders often experience symptoms such as dysphagia and drooling. Studies have shown that the incidence of dysphagia in Parkinson's disease patients ranges from 11% to 87%. More than 50% of patients with acute ischemic stroke have varying degrees of dysphagia. The incidence of dysphagia in stroke patients is approximately 51%-73%. Since dysphagia is almost universal in PBA patients, capsules are not suitable for them, as swallowing capsules would increase their discomfort.
[0004] CN113209042, CN107072990 and Journal of Affective Disorders (2014), 167,333-335 disclose dextromethorphan quinidine capsules and ordinary tablets, which cannot meet the medication needs of patients with dysphagia.
[0005] Pharm Dev Technol. 24(6), 711-719, 2019, disclosed that sodium stearate fumarate, a lubricant in dextromethorphan hydrobromide orally disintegrating tablets, can enhance the masking effect. Chem. Pharm. Bull. 50(12), 1589-1593, 2002, disclosed the masking effect and possible masking mechanism of sucralose, aspartame, sodium chloride, phosphatidic acid, and tannic acid on the optical isomer of quinidine, showing that the use of electronic sensors (electronic tongue) and human tasting can obtain consistent bitterness evaluation results. However, neither of the above two articles on masking did disclose the masking effect of dextromethorphan-quinidine compositions. In previous research, the inventors of this application found that for dextromethorphan-quinidine compositions, after adding different concentrations of commonly used flavoring agents, the evaluation results of the electronic tongue showed that the bitterness, sourness, and other tastes of the composition were basically not improved. Therefore, it is necessary to conduct in-depth research and screening on the masking effect of dextromethorphan-quinidine compositions.
[0006] In conclusion, to alleviate patient suffering, there is an urgent need to develop a new dosage form of dextromethorphanidine that can simultaneously mask the taste and facilitate swallowing. Summary of the Invention
[0007] The purpose of this invention is to solve the problems in the prior art and provide a dextromethorphanidine composition that is easy to swallow and has a good taste, its preparation method and application.
[0008] The objective of this invention can be achieved through the following technical solutions: The present invention provides a dextromethorphan-quinidine composition comprising a dextromethorphan resin complex and a quinidine resin complex.
[0009] In this invention, "dextromethorphan" in the dextromethorphan-quinidine composition, dextromethorphan resin complex, and quinidine resin complex refers to dextromethorphan, its pharmaceutically acceptable salts, or their hydrates, including but not limited to hydrobromide, hydrochloride, phosphate, hydroiodide, nitrate, formate, sulfate, acetate, propionate, butyrate, trifluoroacetate, p-toluenesulfonate, lysine, N,N'-dibenzylethylenediamine, procaine, chloroprocaine, diethylene glycolamine, ethylenediamine, meglumine, lithium, sodium, potassium, calcium, magnesium, or hydrates of the above salts, preferably hydrobromide, hydrochloride, phosphate, hydroiodide, or the above salts. The hydrate of the salt is more preferably hydrobromide or hydrobromide hydrate; "quinidine" refers to quinidine, its pharmaceutically acceptable salt or its hydrate, including but not limited to sulfate, polygalacturonate, hydrochloride, hydroiodate, hydrobromide, phosphate, nitrate, oxalate, p-toluenesulfonate, gluconate, lysine salt, N,N'-dibenzylethylenediamine salt, procaine salt, chloroprocaine salt, diethylene glycolamine salt, ethylenediamine salt, meglumine salt, lithium salt, sodium salt, potassium salt, calcium salt, magnesium salt or hydrate of the above salts, preferably sulfate, polygalacturonate, hydrochloride or hydrate of the above salts, more preferably sulfate or sulfate hydrate.
[0010] Both dextromethorphan and quinidine have unpleasantly bitter and numbing tastes, requiring taste masking to produce easily swallowable oral formulations. However, adding masking agents often hinders the dissolution of the active ingredients, especially for compositions where the masking effect and dissolution of dextromethorphan and quinidine need to be considered separately; it is difficult to obtain formulations that simultaneously meet the requirements of both masking and dissolution. The inventors of this application have formulated dextromethorphan and quinidine into a resin complex, which satisfies the dissolution requirements of the formulation while effectively masking the taste of dextromethorphan and quinidine. Furthermore, the resin complex facilitates the formulation of various easily swallowable preparations.
[0011] In a preferred embodiment, the dextromethorphan resin complex of the present invention comprises dextromethorphan, a pharmaceutically acceptable salt thereof or its hydrate, and an ion exchange resin.
[0012] In a preferred embodiment, the quinidine resin complex of the present invention comprises quinidine, a pharmaceutically acceptable salt thereof or a hydrate thereof, and an ion exchange resin.
[0013] In a preferred embodiment, the ion exchange resin in the resin composite of the present invention is selected from acrylic resins or polyvinyl alcohol resins, preferably divinylbenzene methacrylate polymers, styrene methacrylate polymers, divinylbenzene acrylate polymers, styrene and divinylbenzene polymers, or phenolic polyamine divinylbenzene polymers; the functional groups of the ion exchange resin are preferably carboxyl groups and sulfonic acid groups. Preferably, the ion exchange resin in the resin composite of the present invention is selected from resins with an exchange capacity of 2 meq / kg to 12 meq / kg. More preferably, the ion exchange resin in the resin composite of the present invention is selected from one or more of IRP88, IRP70, IRP64, IRP69, or T-114, more preferably IRP88.
[0014] In this invention, IRP88 refers to AMBERLITE IRP88, IRP70 refers to AMBERLITE IRP70, IRP64 refers to AMBERLITE IRP64, IRP69 refers to AMBERLITE IRP69, and T-114 refers to KYRON T-114.
[0015] In a preferred embodiment, the mass of the ion exchange resin in the dextromethorphan resin complex is 2 to 4 times that of dextromethorphan, its pharmaceutically acceptable salt or its hydrate, quinidine, its pharmaceutically acceptable salt or its hydrate, preferably 2 times.
[0016] As the amount of ion exchange resin added increases, the resin's masking effect on dextromethorphan and quinidine improves. However, the more ion exchange resin added, the greater the total weight of the formulation, which increases the difficulty of swallowing and also hinders the dissolution of dextromethorphan and quinidine.
[0017] In a preferred embodiment, the concentration of dextromethorphan, its pharmaceutically acceptable salt or hydrate thereof, quinidine, its pharmaceutically acceptable salt or hydrate thereof in the aqueous solution of the dextromethorphan resin complex and the quinidine resin complex is 2 mg / mL or more, preferably 2-4 mg / mL, and more preferably 3-4 mg / mL.
[0018] The inventors of this application have discovered that the concentration of dextromethorphan or quinidine has a significant impact on the final taste-masking effect during the preparation of the resin complex. When the concentration is above 2 mg / mL, the adsorption rate of dextromethorphan or quinidine by the ion exchange resin is greater than 90%, exhibiting a good taste-masking effect. When the concentration is above 3 mg / mL, the adsorption rate of dextromethorphan or quinidine by the ion exchange resin is greater than 90% after 10 minutes, demonstrating excellent preparation efficiency and significantly reducing costs in industrial production.
[0019] In a preferred embodiment, the dextromethorphanidine composition provided by the present invention can be formulated into an oral formulation, which may be granules, orally disintegrating tablets, solutions, capsules or tablets, preferably granules, orally disintegrating tablets or solutions.
[0020] By mixing the dextromethorphan resin complex and quinidine resin complex obtained in this invention with commonly used excipients and employing conventional formulation preparation processes, easily swallowable oral formulations of dextromethorphan and quinidine can be readily and conveniently prepared. Examples include dextromethorphan and quinidine granules, orally disintegrating tablets, and solutions.
[0021] Another object of the present invention is to provide the use of a dextromethorphan quinidine composition in the preparation of a medicament for the treatment and / or prevention of pseudobulbar mood, dysphagia, drooling or speech disorders, and cognitive deficits in patients with neurological disorders.
[0022] Compared with existing technologies, this invention provides a resin composition for dextromethorphanidine that satisfies both taste masking and pharmaceutical requirements. The resin composition is easily prepared into easily swallowable granules, orally disintegrating tablets, or solutions, solving the swallowing difficulties of patients with neurological disorders and greatly improving their medication experience. Furthermore, the composition provided by this invention has similar dissolution effects to the original drug, a simple preparation process, low cost, and safety, making it suitable for large-scale industrial production. Detailed Implementation
[0023] The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.
[0024] Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available products or can be prepared by known methods.
[0025] Example 1 Weigh 1.6 g of dextromethorphan hydrobromide and 1.6 g of quinidine sulfate, and dissolve them separately in 400 mL of purified water. Add 1 g of ion exchange resin to each at 37 °C, stir for 20 h, centrifuge, and wash and dry the resulting solids to obtain dextromethorphan hydrobromide resin complex and quinidine sulfate resin complex.
[0026] During the preparation of the resin complex, 2 mL of solution was taken at different time points (min), centrifuged, filtered, and the concentration of the remaining active ingredients in the solution was detected. The adsorption rate (%) of the ion exchange resin for dextromethorphan or quinidine was calculated, and the results are shown in Table 1.
[0027] The results showed that all ion exchange resins adsorbed dextromethorphan hydrobromide or quinidine sulfate relatively quickly, with adsorption rates reaching over 80% within 5 minutes.
[0028] The prepared dextromethorphan resin complex and quinidine resin complex were subjected to artificial taste testing. The tasting method was as follows: volunteers refrained from eating, drinking, or chewing gum for at least 1 hour before the test and rinsed their mouths with deionized water. Volunteers first rinsed their mouths with warm water at least 3 times until no odor remained, then held the sample in their mouths for 10 seconds before spitting it out, and then rinsed their mouths with warm water at least 10 times until no taste remained before proceeding to the next sample test. Volunteers evaluated the bitterness, numbing sensation, sourness, and sweetness of the samples they tasted. The percentage of volunteers voting for each evaluation item was counted, and this percentage was multiplied by the corresponding taste coefficient to obtain the score for that evaluation item. The taste coefficients for each evaluation item were: extremely bitter: 60, bitter: 40, slightly bitter: 20, not bitter: 0, numbing sensation: 40, sour: 10, sweet: 0. The scores for each item were accumulated to obtain the total score, and the results are shown in Table 2. The lower the total score, the better the taste correction effect.
[0029] The results showed that all ion exchange resins could improve the bitterness and numbing sensation of dextromethorphan and quinidine. Under the conditions of this embodiment, IRP69, IRP70, and IRP88 could all improve the bitterness of dextromethorphan and quinidine to an acceptable level of slight bitterness or better, and IRP70 and IRP88 could completely mask the numbing sensation of dextromethorphan and quinidine.
[0030] The dissolution of the prepared dextromethorphan resin complex and quinidine resin complex in simulated gastric juice (NaCl concentration of 2 g / L) at pH 1.2 without pepsin was detected, and the results are shown in Table 3.
[0031] The results showed that the formation of resin complexes significantly inhibited the dissolution of dextromethorphan and quinidine. Only the resin complexes formed by IRP88 with dextromethorphan and quinidine achieved a dissolution rate of over 90% within 15 minutes, meeting the dissolution requirements for immediate-release formulations.
[0032] Example 2 Weigh out dextromethorphan hydrobromide and quinidine sulfate, and prepare aqueous solutions of 2.33 mg / mL. Add IRP88 resin at 37°C, stir, centrifuge, wash and dry the solids to obtain dextromethorphan resin complex and quinidine resin complex.
[0033] Following the above method, dextromethorphan resin complexes and quinidine resin complexes with different mass ratios were prepared. The masking effect of the prepared resin complexes was examined using the artificial taste test method described in Example 1, and the results are shown in Table 4.
[0034] The results showed that the masking effect of IRP88 on dextromethorphan and quinidine increased with increasing IRP88 dosage. When the mass of IRP88 was twice or more than the mass of dextromethorphan hydrobromide or quinidine sulfate, its masking effect on both dextromethorphan and quinidine was good. However, considering the masking results of 1g IRP88 on 1.6g of dextromethorphan hydrobromide and quinidine sulfate in Example 1, it indicates that the concentration of the active ingredient also affects the final masking effect during the preparation of the resin complex.
[0035] Example 3 Weigh 1.2 g of dextromethorphan hydrobromide and 1.2 g of quinidine sulfate, and add appropriate amounts of deionized water to prepare dextromethorphan hydrobromide solutions and quinidine sulfate solutions with concentrations of 1 mg / mL, 2 mg / mL, 3 mg / mL, and 4 mg / mL, respectively. Add 2.4 g of IRP88 resin to each solution at 37 °C, centrifuge, and dry the solids to obtain dextromethorphan resin complexes or quinidine resin complexes.
[0036] The adsorption rate (%) of IRP88 for the drug was calculated using the same method as in Example 1, and the results are shown in Table 5.
[0037] The results showed that when the amount of resin added was twice the mass of dextromethorphan or quinidine, the adsorption rate of IRP88 resin for dextromethorphan or quinidine increased with the increase of dextromethorphan or quinidine concentration. When the solution concentration of dextromethorphan hydrobromide or quinidine sulfate was 2 mg / mL or higher, the adsorption rate of IRP88 resin for dextromethorphan or quinidine was not lower than that in Example 1. When the solution concentration of dextromethorphan hydrobromide or quinidine sulfate was 3 mg / mL or higher, the adsorption rate was greater than 90% after 10 min of reaction, which can save a lot of costs in industrial production.
[0038] Example 4 Weigh 1.2 g of dextromethorphan hydrobromide and 1.2 g of quinidine sulfate, add appropriate amounts of deionized water to prepare solutions with a concentration of 4 mg / mL, stir at 37 °C until dissolved, add 2.4 g of IRP88 resin, stir, centrifuge, wash the resulting solids with deionized water and dry to obtain a dextromethorphan resin complex with a drug loading of 31.3% (w / w) and a quinidine resin complex with a drug loading of 31.8% (w / w).
[0039] The masking effect of the obtained resin complex was investigated according to the tasting method described in Example 1. The results showed that the bitterness and numbing sensation of dextromethorphan and quinidine were both masked.
[0040] The above-mentioned dextromethorphan resin complex, quinidine resin complex, and one or more fillers, lubricants, and disintegrants are prepared into a dextromethorphan-quinidine composition according to conventional preparation methods.
[0041] Example 5 Weigh 63.8 mg of the dextromethorphan hydrobromide resin complex and 31.4 mg of the quinidine sulfate resin complex prepared in Example 4, mix them evenly to obtain the dextromethorphan hydrobromide and quinidine sulfate composition.
[0042] The dissolution rates of the dextromethorphan hydrobromide and quinidine sulfate combination and the marketed Nuedexta capsules were compared according to the FDA-recommended dissolution method [basket method, simulated gastric juice without pepsin at pH 1.2 (NaCl concentration of 2 g / L), 37°C]. The results are shown in Table 6.
[0043] The results show that the dissolution rate of the dextromethorphan hydrobromide and quinidine sulfate composition of the present invention is basically consistent with that of the marketed Nuedexta capsules, exhibiting excellent dissolution characteristics and meeting the dissolution rate requirements of immediate-release formulations.
[0044] It should be noted that the above-described preferred embodiments are further, non-limiting, detailed descriptions of the technical solutions of the present invention, and are only intended to illustrate the technical concept and features of the present invention. Their purpose is to enable those skilled in the art to understand and implement the present invention, and they should not be construed as limiting the scope of protection of the present invention. All equivalent changes or modifications made according to the spirit and essence of the present invention should be covered within the scope of protection of the present invention.
Claims
1. A dextromethorphan quinidine composition characterized by: The composition comprises a dextromethorphan resin complex and a quinidine resin complex, and the composition does not contain a bioadhesive coating layer; wherein the dextromethorphan resin complex comprises dextromethorphan, a pharmaceutically acceptable salt thereof or its hydrate, and an ion exchange resin; and the quinidine resin complex comprises quinidine, a pharmaceutically acceptable salt thereof or its hydrate, and an ion exchange resin. The ion exchange resin is IRP88; The mass of the ion exchange resin is 2-4 times that of dextromethorphan, its pharmaceutically acceptable salt or its hydrate, quinidine, its pharmaceutically acceptable salt or its hydrate; When preparing the resin complex, the concentration of dextromethorphan, its pharmaceutically acceptable salt or its hydrate, quinidine, its pharmaceutically acceptable salt or its hydrate in the aqueous solution is 2-4 mg / mL; The composition is an orally disintegrating tablet.
2. The composition of claim 1, wherein: The mass of the ion exchange resin is twice that of dextromethorphan, its pharmaceutically acceptable salt or its hydrate, quinidine, its pharmaceutically acceptable salt or its hydrate.
3. The composition of claim 2, wherein: Dextromethorphan, its pharmaceutically acceptable salt or its hydrate, and quinidine, its pharmaceutically acceptable salt or its hydrate, are present in aqueous solutions at concentrations of 3-4 mg / mL.
4. Use of the composition of claim 1 in the preparation of a medicament for the treatment and / or prevention of pseudobulbar mood, dysphagia, drooling or speech disorders, and cognitive deficits in patients with neurological disorders.
Citation Information
Patent Citations
Drug-release controlled dry suspension containing medical resin compound and preparation method thereof
CN108030770A
Dextromethorphan quinidine orally disintegrating tablet and application thereof
CN114469882A
